Enterprise Value to EBITDA Multiple ratio Analysis of BioCryst Pharmaceuticals Inc - Deep Dive
Birds's Eye
Fundamentals
Fundamentals
Technicals
MovingAverage
Candlestick
PivotPointLatest FY EV to EBITDA
Period Ending - Dec-23
Very Poor EV to EBITDA
-15.80
Period Ending - Dec-22
Very Poor EV to EBITDA
-10.90
Growth
-44.87 %
Trailing Twelve Months EV to EBITDA
Period Ending - Dec-23
Very Poor EV to EBITDA
-26.76
EV to EBITDA Analysis of BioCryst Pharmaceuticals Inc
| EV to EBITDA Ratio of BCRX drastically fell by -44.87 % this year. |
| EV to EBITDA Ratio with value of -5.73 was highest in Year Dec-20 in last Five Years. |
| EV to EBITDA Ratio of BCRX trending down for at least three Years. |
| Latest EV to EBITDA Ratio with value of -15.80 is lower than Average EV to EBITDA of -10.01 in last five years. |
Other EV to EBITDA Related Info of BCRX that may interest you.
BioCryst Pharmaceuticals Inc Overview
| Code | Price | Previous Price | Price Change | Sector |
|---|---|---|---|---|
| BCRX | 6.46 | 6.57 | 1.67 % | Biotechnology |
Defination of Enterprise Value to EBITDA Multiple
Enterprise Value-to-EBITDA Ratio is used to compare a company's Enterprise Value to its EBITDA (Earnings before Interest, Taxes, Depreciation, and Amortization). It is useful to determine the value of a company, whether it is undervalued or overvalued. more ..
EV to EBITDA Related Ratios
| EBITDAMargin | EVToRevenue | PriceToEarningRatio |
Tsr Value Index
| Poor Value Stock | |
FY - Historical Enterprise Value to EBITDA Multiple of BioCryst Pharmaceuticals Inc
| Period | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 |
|---|---|---|---|---|---|---|---|
| EV to EBITDA | -15.80 | -10.90 | -10.19 | -5.73 | -7.41 | -7.66 | -9.68 |
| Change | -44.87 % | -7.05 % | -77.91 % | 22.78 % | 3.15 % | 20.95 % | 7.63 % |
FY Chart of Enterprise Value to EBITDA Multiple of BioCryst Pharmaceuticals Inc
Note : All Data Generated at the End of Trading Hours (EOD Data)